Questcor Pharmaceuticals, Inc.

Questcor Pharmaceuticals, Inc. company information, Employees & Contact Information

Now a part of Mallinckrodt Pharmaceuticals Mallinckrodt Pharmaceuticals is pleased to bring Questcor and its entire business into our company. The former Questcor organization will be known as the Autoimmune and Rare Diseases business within Mallinckrodt’s Specialty Pharmaceuticals segment. We will continue their focus on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders, primarily in the fields of neurology, nephrology, rheumatology and pulmonology, areas of medicine which have significant unmet medical needs. A market-leader in specialty pharmaceuticals and medical imaging, Mallinckrodt develops, manufactures and markets products that diagnose serious illnesses and treat pain. Our pharmaceuticals business encompasses branded and generic products as well as the Active Pharmaceuticals Ingredients used to make prescription drugs. Our imaging business focuses on contrast media and delivery systems plus nuclear medicine. Together we will work tirelessly to find more imaginative ways to help more patients, accelerate product development and deliver long-term, above-market growth. Corporate Culture It’s an exciting time to be at Mallinckrodt. Our culture is defined by five hallmarks: high-performing, competitive, collaborative, engaged and trustworthy. There’s a strong sense of purpose, too, as we’re all totally focused on helping patients, whether we’re producing quality products, engaged in customer service or educating healthcare professionals. Our culture encourages collaboration, breakthrough thinking and ownership of meaningful work. We’ll empower you to act in the best interests of our customers and our company. The more you’re alert to opportunities, inspired to take the initiative and ready to make thoughtful decisions, the more successful you will be. Combine your competitive zeal with the passion to improve lives, and you’ll soon find yourself building your career as well as our business.

Company Details

Employees
66
Address
Hayward, Ca 94545, Us
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Hayward, CA
Looking for a particular Questcor Pharmaceuticals, Inc. employee's phone or email?

Questcor Pharmaceuticals, Inc. Questions

News

Mallinckrodt plc to Report Third Quarter 2025 Financial Results on November 10, 2025 - Lelezard

Mallinckrodt plc to Report Third Quarter 2025 Financial Results on November 10, 2025 Lelezard

Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results - PR Newswire

Mallinckrodt plc to Report Fourth Quarter and Fiscal Year 2024 Financial Results PR Newswire

Mallinckrodt Finalizes Settlement to Resolve "Track 1" Opioid Cases with the Ohio Counties of Cuyahoga and Summit - PR Newswire

Mallinckrodt Finalizes Settlement to Resolve "Track 1" Opioid Cases with the Ohio Counties of Cuyahoga and Summit PR Newswire

Mallinckrodt Announces Board of Directors and Leadership Updates - PR Newswire

Mallinckrodt Announces Board of Directors and Leadership Updates PR Newswire

Mallinckrodt Receives Necessary Ruling from Irish High Court to Combine with Endo, Inc. - PR Newswire

Mallinckrodt Receives Necessary Ruling from Irish High Court to Combine with Endo, Inc. PR Newswire

Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million - PR Newswire

Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital for $250 Million PR Newswire

Mallinckrodt Receives Approval to List on NYSE American - PR Newswire

Mallinckrodt Receives Approval to List on NYSE American PR Newswire

Mallinckrodt plc Reports Third Quarter 2024 Financial Results and Raises Full Year Guidance - PR Newswire

Mallinckrodt plc Reports Third Quarter 2024 Financial Results and Raises Full Year Guidance PR Newswire

Mallinckrodt plc Reports First Quarter 2025 Financial Results and Reaffirms Full-Year Guidance - PR Newswire

Mallinckrodt plc Reports First Quarter 2025 Financial Results and Reaffirms Full-Year Guidance PR Newswire

Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year Guidance - PR Newswire

Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year Guidance PR Newswire

Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million - PR Newswire

Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million PR Newswire

Mallinckrodt, Endo Announce Planned Leadership Team for Merged Company - PR Newswire

Mallinckrodt, Endo Announce Planned Leadership Team for Merged Company PR Newswire

Mallinckrodt Gains Support for Its Restructuring Support Agreement from Lenders Holding Approximately $1.3 Billion of Its First Lien Term Loans - PR Newswire

Mallinckrodt Gains Support for Its Restructuring Support Agreement from Lenders Holding Approximately $1.3 Billion of Its First Lien Term Loans PR Newswire

Mallinckrodt Completes Financial Restructuring and Irish Examinership Proceedings and Emerges From Chapter 11 - PR Newswire

Mallinckrodt Completes Financial Restructuring and Irish Examinership Proceedings and Emerges From Chapter 11 PR Newswire

Mallinckrodt and Endo Announce Significant Progress in Proposed Merger - PR Newswire

Mallinckrodt and Endo Announce Significant Progress in Proposed Merger PR Newswire

Mallinckrodt Completes Divestiture of Therakos® Business - PR Newswire

Mallinckrodt Completes Divestiture of Therakos® Business PR Newswire

Mallinckrodt plc Provides Update on Executive Committee - PR Newswire

Mallinckrodt plc Provides Update on Executive Committee PR Newswire

Mallinckrodt Opens Specialty Brands Office In New Jersey, Announces $100,000 Donation To Princeton University Program For High Achieving, Low-Income High School Students - PR Newswire

Mallinckrodt Opens Specialty Brands Office In New Jersey, Announces $100,000 Donation To Princeton University Program For High Achieving, Low-Income High School Students PR Newswire

Mallinckrodt Plans Spin-Off of Specialty Generics Business to Shareholders - PR Newswire

Mallinckrodt Plans Spin-Off of Specialty Generics Business to Shareholders PR Newswire

Mallinckrodt Enters Agreement To Sell Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million - PR Newswire

Mallinckrodt Enters Agreement To Sell Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million PR Newswire

Mallinckrodt Locates Growing Specialty Brands Businesses In Bedminster, N.J.; Continues Significant St. Louis Reinvestment - PR Newswire

Mallinckrodt Locates Growing Specialty Brands Businesses In Bedminster, N.J.; Continues Significant St. Louis Reinvestment PR Newswire

Mallinckrodt's Hobart, N.Y. Site Recognized With Two Manufacturing Leadership Awards - PR Newswire

Mallinckrodt's Hobart, N.Y. Site Recognized With Two Manufacturing Leadership Awards PR Newswire

Mallinckrodt Completes Sale Of Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million - PR Newswire

Mallinckrodt Completes Sale Of Its Nuclear Imaging Business To IBA Molecular For Approximately $690 Million PR Newswire

Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, Inc. - PR Newswire

Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, Inc. PR Newswire

Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products - PR Newswire

Mallinckrodt Completes Acquisition Of Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products PR Newswire

Mallinckrodt and Endo Merger Update - citybiz

Mallinckrodt and Endo Merger Update citybiz

Mallinckrodt To Sell Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately $203 Million - PR Newswire

Mallinckrodt To Sell Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately $203 Million PR Newswire

Mallinckrodt Completes Acquisition of InfaCare Pharmaceutical Corporation and Stannsoporfin, its Proprietary Therapy in Late-Stage Development for Newborns at Risk for Severe Jaundice - PR Newswire

Mallinckrodt Completes Acquisition of InfaCare Pharmaceutical Corporation and Stannsoporfin, its Proprietary Therapy in Late-Stage Development for Newborns at Risk for Severe Jaundice PR Newswire

Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases - PR Newswire

Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases PR Newswire

Mallinckrodt Completes Sale Of Its Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately $203 Million - PR Newswire

Mallinckrodt Completes Sale Of Its Intrathecal Therapy Business To Piramal Enterprises Limited For Approximately $203 Million PR Newswire

Mallinckrodt Completes Acquisition of Ocera Therapeutics and OCR-002, Its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy - PR Newswire

Mallinckrodt Completes Acquisition of Ocera Therapeutics and OCR-002, Its Proprietary Therapy in Development for Treatment of Hepatic Encephalopathy PR Newswire

Mallinckrodt And Federal Trade Commission Resolve Questcor Matter - PR Newswire

Mallinckrodt And Federal Trade Commission Resolve Questcor Matter PR Newswire

Mallinckrodt Pharmaceuticals distributes more than 2K gallons of hand sanitizer to Missouri - The Missouri Times

Mallinckrodt Pharmaceuticals distributes more than 2K gallons of hand sanitizer to Missouri The Missouri Times

Mallinckrodt and Endo to Merge - citybiz

Mallinckrodt and Endo to Merge citybiz

Mallinckrodt To Acquire Ocera Therapeutics And OCR-002, Its Proprietary Therapy In Development For Treatment Of Hepatic Encephalopathy - PR Newswire

Mallinckrodt To Acquire Ocera Therapeutics And OCR-002, Its Proprietary Therapy In Development For Treatment Of Hepatic Encephalopathy PR Newswire

Mallinckrodt Completes Expansion of Operations and Manufacturing Facility for StrataGraft® Regenerative Skin Tissue in Madison, Wis. - PR Newswire

Mallinckrodt Completes Expansion of Operations and Manufacturing Facility for StrataGraft® Regenerative Skin Tissue in Madison, Wis. PR Newswire

Mallinckrodt Builds Leadership To Support Continued Growth - PR Newswire

Mallinckrodt Builds Leadership To Support Continued Growth PR Newswire

Mallinckrodt's SpecGx LLC Reports on Outcome of FDA Joint Advisory Committee on Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone® (Oxycodone Hydrochloride) - PR Newswire

Mallinckrodt's SpecGx LLC Reports on Outcome of FDA Joint Advisory Committee on Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone® (Oxycodone Hydrochloride) PR Newswire

Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million - PR Newswire

Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million PR Newswire

Mallinckrodt Announces UVADEX® (Methoxsalen) Approved in Australia for use with the THERAKOS® CELLEX® Photopheresis System for Treatment of Chronic Graft Versus Host Disease (cGvHD) and Skin Manifestations of Cutaneous T-Cell Lymphoma (C - PR Newswire

Mallinckrodt Announces UVADEX® (Methoxsalen) Approved in Australia for use with the THERAKOS® CELLEX® Photopheresis System for Treatment of Chronic Graft Versus Host Disease (cGvHD) and Skin Manifestations of Cutaneous T-Cell Lymphoma (C PR Newswire

Mallinckrodt Earns International Standard ISO 13485:2016 and Medical Device Single Audit Program (MDSAP) Certifications for INOmax® DSIR® Plus Nitric Oxide Delivery Systems - PR Newswire

Mallinckrodt Earns International Standard ISO 13485:2016 and Medical Device Single Audit Program (MDSAP) Certifications for INOmax® DSIR® Plus Nitric Oxide Delivery Systems PR Newswire

Mallinckrodt's SpecGx LLC Receives FDA Complete Response Letter for Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone® (Oxycodone Hydrochloride) - PR Newswire

Mallinckrodt's SpecGx LLC Receives FDA Complete Response Letter for Abuse-Deterrent, Immediate-Release Reformulation of Roxicodone® (Oxycodone Hydrochloride) PR Newswire

Mallinckrodt To Acquire InfaCare Pharmaceutical Corporation And Stannsoporfin, Its Proprietary Therapy In Late-Stage Development For Treatment Of Newborns At Risk For Developing Severe Jaundice - PR Newswire

Mallinckrodt To Acquire InfaCare Pharmaceutical Corporation And Stannsoporfin, Its Proprietary Therapy In Late-Stage Development For Treatment Of Newborns At Risk For Developing Severe Jaundice PR Newswire

Mallinckrodt Supports Investigator-Initiated Study at Massachusetts General Hospital to Assess Effectiveness of Inhaled Nitric Oxide in Patients with Severe Acute Respiratory Distress Syndrome Due to COVID-19 - PR Newswire

Mallinckrodt Supports Investigator-Initiated Study at Massachusetts General Hospital to Assess Effectiveness of Inhaled Nitric Oxide in Patients with Severe Acute Respiratory Distress Syndrome Due to COVID-19 PR Newswire

Mallinckrodt To Acquire Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products - PR Newswire

Mallinckrodt To Acquire Stratatech Corporation, A Regenerative Medicine Company Focused On Proprietary Therapeutic Human Skin Substitute Products PR Newswire

Ventilators - respiratory-therapy.com

Ventilators respiratory-therapy.com

IBA Molecular Acquires Mallinckrodt Nuclear Imaging - Imaging Technology News

IBA Molecular Acquires Mallinckrodt Nuclear Imaging Imaging Technology News

Mallinckrodt Announces Donation of Two Transport Vehicles to Coolmine Therapeutic Community (TC) - PR Newswire UK

Mallinckrodt Announces Donation of Two Transport Vehicles to Coolmine Therapeutic Community (TC) PR Newswire UK

Top Questcor Pharmaceuticals, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant